2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2457

An Open-Label Prospective Pilot Mechanistic Study of Fluvastatin in Persistently Antiphospholipid Antibody-Positive Patients
Abstract Number: 1655

An Open-Label Trial of Abatacept in Mild Relapsing Granulomatosis with Polyangiitis (Wegener’s)
Abstract Number: 2172

An Update of Management of Coccidioidomycosis in Patients On Biologic Response Modifiers and Disease-Modifying Antirheumatic Drugs
Abstract Number: 1310

Analysis of Anti-JC Polyomavirus T-Cell Immune Response with JC-Feron in Patients with Rheumatoid Arthritis Treated with Rituximab or Anti-TNF
Abstract Number: 761

Analysis of Biomarkers in Systemic Juvenile Idiopathic Arthritis Patients On Canakinumab Therapy
Abstract Number: 2229

Analysis of Clinical, CRP- and MRI- Responses to TNF-Blockade in Axial Spondyloarthritis Patients with Short Vs Long Symptom Duration
Abstract Number: 2143

Analysis of Factors Associated with the Health Assessment Questionnaire Score Change in Five Years
Abstract Number: 392

Analysis of Factors Impact On Patient Global Assessment in Daily Practice Based On Observational Cohort IORRA (Institute of Rheumatology, Rheumatoid Arthritis)
Abstract Number: 1196

Analysis of Gene Expression Patterns in Rheumatoid Arthritis (RA) Synovial Macrophages From Patients Undergoing Disease Flare
Abstract Number: 191

Analysis of Genes Involved in Autoinflammatory Diseases in Adult Onset Still’s Disease
Abstract Number: 1015

Analysis of Integrated Radiographic Data for Two Long-Term, Open-Label Extension Studies of Adalimumab
Abstract Number: 2057

Analysis of the Adherence to the Monitoring of Glucocorticoid Eye Toxicity and of the Prevalence of Cataracts and Glaucoma Among Patients with Systemic Lupus Erythematosus
Abstract Number: 1614

Analysis of the Immunochip in a Large Cohort of Juvenile Idiopathic Arthritis Cases Identifies 17 Loci At Genome-Wide Significance
Abstract Number: 1538

ANCA-Associated Vasculitis in Hispanic Americans: An Unrecognized Severity
Abstract Number: 303

Ancestral Group Differences in Pediatric SLE Early Disease Severity: An Analysis of the Carranet Registry

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].